Business Context and Reporting Period
This is Repro Med Systems, Inc.’s (d/b/a RMS Medical Products) Form 10-K for the fiscal year ended December 31, 2018—not a standalone fourth-quarter report. The filing metadata names KORU Medical Systems, Inc.; the filing itself identifies Repro Med Systems, Inc. and ticker REPR, so the entity identity should be verified.
The company designs, manufactures and sells portable infusion devices and related accessories, principally its FREEDOM infusion systems, for home and alternate-site care. The fiscal year-end had previously been February 28; consequently, the reported 2018 twelve-month results are not directly comparable with the prior transition-year ten-month period. The filing also presents a full-year 2017 comparison.
Key Financial Results
| Metric | FY 2018 | FY 2017 | Change |
|---|---|---|---|
| Net sales | $17.35 million | $15.44 million | Up 12.4% |
| Gross profit / gross margin | $10.81 million / 62.3% | $9.27 million / 60.0% | Margin up 2.3 percentage points |
| Operating expenses | $9.65 million | $8.12 million | Up approximately 18.8% |
| Operating profit | $1.16 million | $1.15 million | Up approximately 1.2% |
| Net income | $0.91 million | $0.82 million | Up 11.1% |
| Basic and diluted EPS | $0.02 | $0.02 | No change |
| Operating cash flow | $1.48 million | $1.35 million | Up approximately 9.5% |
The FY 2017 figures in this table are the filing’s full twelve-month comparison. Against the ten-month 2017 transition period, 2018 sales were $17.35 million versus $13.31 million and net income was $0.91 million versus $0.90 million; those comparisons cover different period lengths.
Domestic sales were $14.24 million, up 12.9%, and international sales were $3.12 million, up 10.3%. Management attributed growth mainly to needle-set sales, greater penetration in the subcutaneous immunoglobulin market, early adoption for the CIDP indication, and increased pharmaceutical customer clinical trials.
At December 31, 2018, cash and cash equivalents were $3.74 million, certificates of deposit were $1.52 million, and current assets totaled $9.03 million. Current liabilities were $1.58 million; total liabilities were also $1.58 million. No amounts were drawn on the $1.5 million revolving credit line. Net cash used in investing activities was $1.73 million, including a $1.5 million certificate-of-deposit purchase, capital expenditures and patent spending. Cash and cash equivalents declined by $0.24 million during the year.
Material Changes and Unusual Items
- Gross margin improved from 60.0% to 62.3%. Management credited operating efficiencies and a nondestructive testing protocol introduced in January 2018 that reduced scrap.
- SG&A and research and development expenses rose. The company reported $996,447 in reorganization charges, including executive and senior-management changes, special-committee legal work, director recruitment, and costs associated with a stock purchase agreement. Management cited approximately $0.8 million of legal expenses and $0.6 million of severance, signing bonuses, option issuances and recruiting costs among the drivers of higher expenses.
- Management’s non-GAAP adjusted EBITDA was $2.75 million for 2018 versus $1.58 million for 2017; non-GAAP normalized net income was $1.70 million versus $0.82 million. These measures add back or adjust for specified items and are not substitutes for GAAP results.
- Leadership and board composition changed substantially during 2018. Donald Pettigrew became CEO in February 2019; Daniel Goldberger became Executive Chairman.
Outlook, Risks and Contingencies
- The strategic plan approved in January 2019 targets, through 2022, a $50 million net-revenue run rate, gross margins above 70%, and annual organic revenue growth above 20%. These are goals, not a guarantee of results or near-term guidance.
- Management said cash and expected operating cash flows should fund operations, R&D and capital expenditures for the next 12 months. The company planned additional R&D investment.
- Customer and channel concentration is significant: one customer generated approximately 58% of FY 2018 gross product revenue, and five distributors represented about 75% of gross revenue. The largest distributor alone represented approximately 58% of gross revenue.
- The company is litigating multiple claims with competitor EMED involving alleged patent infringement, antitrust, defamation and unfair business practices. Monetary damages sought were unspecified. One trial was scheduled for August 2019 and another matter was expected to go to trial in late 2019 or early 2020; outcomes could materially affect results and cash flows.
- Other material risks include reliance on single-source suppliers and one manufacturing facility, regulatory and FDA-clearance requirements, product quality and liability exposure, availability of immunoglobulin drugs, reimbursement and pricing pressure, foreign-market and currency exposure, and the UK’s pending exit from the EU.
- The company’s headquarters and manufacturing site are leased from an entity associated with a director. The lease was extended through optional six-month renewals, with monthly rent of $12,088 beginning March 2019. Management was seeking a larger facility and expected relocation and compliance costs if it moved.
- The audit opinion was unqualified. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not express an opinion on internal control effectiveness.
Most Important Facts for Investors to Verify
- Confirm the issuer: this filing is for Repro Med Systems, Inc. (REPR), despite the request metadata naming KORU Medical Systems, Inc.
- Use the twelve-month 2017 comparison for year-over-year analysis; the ten-month transition-period comparison overstates growth when treated as a like-for-like measure.
- Assess whether the 2022 strategic targets are supported by execution, capacity, investment and customer demand, particularly given the gap between current revenue and the target run rate.
- Monitor distributor and major-customer concentration, single-source component exposure, and progress toward alternative suppliers or channels.
- Track EMED litigation developments, related legal costs, and any potential liability or restrictions on marketing needle sets.
- Review liquidity after the certificate of deposit’s May 2019 maturity, future facility requirements, and any use of the undrawn credit line or equity financing.
- Consider potential dilution: 2.419 million options were outstanding at year-end, and the board proposed increasing the plan’s authorized shares to 6 million, subject to stockholder approval.